Logo
x

Search category

Subscribe Now

HIV-1 infection

ViiV's Vocabria (cabotegravir- tablet formulation) Receives the US FDA's Approval for the Treatment of HIV-1 infection

ViiV's Vocabria (cabotegravir- tablet formulation) Receives the US FDA's Approval for the Treatment of HIV-1 infection

  • January 22, 2021
Gilead's Biktarvy (Bictegravir- Emtricitabine and Tenofovir Alafenamide) Receives NMPA's Approval for Treatment of HIV-1 Infection

Gilead's Biktarvy (Bictegravir- Emtricitabine and Tenofovir Alafenamide) Receives NMPA's Approval for Treatment of HIV-1 Infection

  • August 12, 2019
ViiV Healthcare Reports Submission of MAA to EMA for the Combination of Cabotegravir + Rilpivirine to Treat HIV-1 Infection

ViiV Healthcare Reports Submission of MAA to EMA for the Combination of Cabotegravir + Rilpivirine to Treat HIV-1 Infection

  • July 29, 2019
ViiV Healthcare Reports Results of Fostemsavir in P-III BRIGHTE Study for HIV-1 infection

ViiV Healthcare Reports Results of Fostemsavir in P-III BRIGHTE Study for HIV-1 infection

  • July 23, 2019
ViiV Healthcare Reports Results of Dual-Drug Regimen in P-III TANGO Study for HIV-1 Infection

ViiV Healthcare Reports Results of Dual-Drug Regimen in P-III TANGO Study for HIV-1 Infection

  • July 10, 2019
ViiV Healthcare Files NDA for Cabotegravir + Edurant (rilpivirine) to the US FDA to Treat HIV-1 Infection in Adults

ViiV Healthcare Files NDA for Cabotegravir + Edurant (rilpivirine) to the US FDA to Treat HIV-1 Infection in Adults

  • April 30, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.